{"id":8230,"date":"2025-11-03T12:52:00","date_gmt":"2025-11-03T12:52:00","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8230"},"modified":"2025-11-03T12:52:00","modified_gmt":"2025-11-03T12:52:00","slug":"kimberly-clark-and-kenvue-unite-to-form-consumer-health-giant","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/11\/03\/kimberly-clark-and-kenvue-unite-to-form-consumer-health-giant\/","title":{"rendered":"Kimberly-Clark and Kenvue Unite to Form Consumer Health Giant"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Kimberly-Clark, the maker of household staples like Kleenex and Huggies, has announced plans to acquire Tylenol producer Kenvue in a cash and stock deal valued at approximately <strong>$48.7 billion<\/strong>.<\/h4>\n\n\n\n<p>The move marks one of the largest mergers in the consumer health sector, aiming to create a global powerhouse in personal care and wellness products.<\/p>\n\n\n\n<p>Under the terms of the agreement, <strong>Kenvue shareholders<\/strong> will receive <strong>$3.50 per share in cash<\/strong> and <strong>0.14625 Kimberly-Clark shares<\/strong> for each Kenvue share, totaling <strong>$21.01 per share<\/strong> based on Friday\u2019s closing prices. Upon completion, <strong>Kimberly-Clark shareholders will own about 54%<\/strong> of the merged company, while <strong>Kenvue investors will hold roughly 46%<\/strong>.<\/p>\n\n\n\n<p>The combined firm is projected to generate <strong>$32 billion in annual net revenues by 2025<\/strong>, supported by an estimated <strong>$1.9 billion in cost savings<\/strong> over the first three years after closing. Kimberly-Clark CEO <strong>Mike Hsu<\/strong>, who will lead the merged company, emphasized the shared vision of leveraging science and technology \u201cto provide extraordinary care\u201d for consumers worldwide.<\/p>\n\n\n\n<p>The company\u2019s headquarters will remain in <strong>Irving, Texas<\/strong>, while maintaining a strong operational presence at Kenvue\u2019s existing sites. Additionally, <strong>three Kenvue board members<\/strong> will join Kimberly-Clark\u2019s board, strengthening governance continuity.<\/p>\n\n\n\n<p>Pending shareholder and regulatory approval, the deal is expected to close in the <strong>second half of next year<\/strong>. Following the announcement, <strong>Kimberly-Clark shares fell more than 15%<\/strong>, while <strong>Kenvue\u2019s stock surged over 20%<\/strong>, reflecting investor reactions to the transformative merger that reshapes the landscape of consumer health and hygiene industries.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/10\/31\/reddit-ceo-says-ai-chatbots-arent-driving-traffic-google-and-direct-visits-still-lead\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Reddit CEO Says AI Chatbots Aren\u2019t Driving Traffic \u2014 Google and Direct Visits Still Lead<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kimberly-Clark, the maker of household staples like Kleenex and Huggies, has announced plans to acquire Tylenol producer Kenvue in a cash and stock deal valued at approximately $48.7 billion. The move marks one of the largest mergers in the consumer health sector, aiming to create a global powerhouse in personal care and wellness products. Under [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1125,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[]},"categories":[361,309],"tags":[421,816,416,418,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8230"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8230"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8230\/revisions"}],"predecessor-version":[{"id":8231,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8230\/revisions\/8231"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1125"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8230"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}